مستشفى الزهراء دبي

AL ZAHRA HOSPITAL DUBAI

Care in Style رعاية راقية



COUNSELLING OF ORAL CHEMOTHERAPY

MEDICATION

ALECENSA (ALECTINIB)

DOSE/FDA INDICATION

- Anaplastic lymphoma kinase
- positive Metastatic non small cell lung cancer
- 600mg PO Bid

MONITORING PARAMETERS

Black Box Warning: None

Baseline&Periodicall: Liver functions Tests,heart rate,Blood Pressure

KEY COUNSELLINS POINTS

Administration

- **Take with food**
- **If dose is missed or vomiting occurs after taking adose,take the next dose at the scheduled time**
- **Store in the original container to protect from light**
- **Pregnancy risk factor:D**

Adverse Drug Effects:

fatigue,constipation, edema,myalgia,dysnea,anemia

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN

MEDICATION

FEMARA (LETROZOLE)

DOSE/FDA INDICATION

- Breast Cancer 2.5mg PO daily

MONITORING PARAMETERS

Base line & Periodically:

Liver functions tests,Billirubin q3-6 months,bone density

KEY COUNSELLINS POINTS

Administration

- **Take with food or on empty stomach with glass of water or juice**
- **Pregnancy factor :X**
- **Avoid pregnancy while on therapy**
- **For post menopausal only**

Adverse Drug Effects:

cardiotoxicity increase ischemic events,muscloskeletal disorders,

sexual dysfunctions vaginal dryness, If hot flushes take tablets at bed time

REFERRENCE:

Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.

NCCN

MEDICATION

ARIMEDIX (ANASTRAZOLE)

DOSE/FDA INDICATION

Breast Cancer .1mg PO daily

MONITORING PARAMETERS

Base line & Periodically:

Liver functions tests,Billirubin q3-6 months,bone density

KEY COUNSELLINS POINTS

Administration

- **Take with food or on empty stomach with glass of water or juice**
- **Pregnancy factor :X**
- **Avoid pregnancy while on therapy**
- **For post menopausal only**

Adverse Drug Effects:

cardiotoxicity increase ischemic events,muscloskeletal disorders,

sexual dysfunction,vaginal dryness, If hot flushes take tablets at bed time

REFERRENCE:

Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.

NCCN

MEDICATION

AROMASINE (EXEMESTANE

DOSE/FDA INDICATION

- Breast Cancer 25 mg Per oral daily

MONITORING PARAMETERS

Base line & Periodically:

Liver functions tests,Billirubin q3-6 months,bone density

KEY COUNSELLINS POINTS

Administration

- **Take after food with glass of water or juice to reduce risk of nausea**
- **Pregnancy factor :X**
- **Avoid pregnancy while on therapy For post menopausal only**

Adverse Drug Effects:

cardiotoxicity increase ischemic events,muscloskeletal disorders,

sexual dysfunction,vaginal dryness, If hot flushes take tablets at bed time

REFERRENCE:

Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.

NCCN

MEDICATION

NOLVADEX (TAMOXIFEN)

DOSE/FDA INDICATION

Breast Cancer 20-40mg Per oral daily

MONITORING PARAMETERS

Black Box Warning:uterine malegnancies,stroke

Baseline & Periodically: CBC,Liver Tests,Platelets

Drug Drug Intercations: clopidogrel may increase tam toxicity
INCREASE INR in patients on warfarin Qt prolongation effect

KEY COUNSELLINS POINTS

Administration

- **Take with or with out food**
- **Doses more than 20 mg / day should be divided BID**
- **For pre & post menopause**
- **Pregnancy factor: D**
- **USE barrier or non hormonal contraceptive while on therapy and for 2 months after discontinuation of therapy**

Adverse Drug Effects:

Asverse Drug Effects:

Cardiotoxicity(risk of thrombosis) Hepatotoxicity(↑liver enzymes) altered menses, fluid retention, if hot flushes take tab at bed time 2ndry malignancies (risk of endometrial & uterine cancer)

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN

MEDICATION

EMEND (APREPITANT)



DOSE/FDA INDICATION

- Anti nausea & vomiting 125mg,80mg,80mg

MONITORING PARAMETERS

Drug Drug Interactions:

Cisapride ,pimozide ,terfenadine may cause

life threatening interaction May decrease warfarin,

oral contraceptives, phenytoin

KEY COUNSELLINS POINTS

Administrationt

- Route of admin:Per oral
- PATIENTS SHOULD RECEIVE PACKAGE OF 3 caps over 3 days Day 1 take 125mg cap by mouth one hr before chemo Day 2&3 take one 80mg cap by mouth each morning for 2 days
- Take with food or on empty stomach with glass of water
- Pregnancy RISK factor: B

Side Effects:

Diarrhea,hiccups,fatigue,constipation, Headache

REFERRENCE:

Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.

NCCN

MEDICATION

BOSULIF (BOSITINIB)

DOSE/FDA INDICATION

- Chronic myeloid leukemia ph+CML Intolerant to prior therapy
  500 mg once daily Per oral

MONITORING PARAMETERS

Black Box Warning:NONE Baseline & periodically: CBC,Serum Creat,Liver Functions Tests ↓ dose to 200mg daily if LFT rise›5XUpper Limit Normal hold till‹2.5XULN resume at 400mg

Crcl 30-50ml/min: 400mg ‹30ml/min: 300mg

Grade +3 diarrhea or myelosuppression ↓ dose by 100mg

Drug Drug Interactions: CYP3A4(diltiazem-amlodipine-alprazolam, vincristine-nisoldipine

KEY COUNSELLINS POINTS

Administrationt

- **Swallow tabs whole, do not crush or chew**
- **Take with food**
- **Avoid grapefruit/juice**
- **Missed dose should be taken if‹12 hrs.**
- **Hazardous agent, use precautions when handling**

Adverse Drug Effects:

Hemorrage,Fatigue,Nausea,

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN

MEDICATION

GLEEVEC (IMATENIB)

DOSE/FDA INDICATION

- Chronic myeloid leukemia ph+CML 400 mg Per oral daily
- Ph+Acute Lymphoblastic Leukemia 600 mg Per oral daily

MONITORING PARAMETERS

Black Box Warning:NONE

Baseline& Periodically CBC,hold if ANC‹1000 & PLTS‹50000 LFTs hold if billirubin ›3x ULN until ‹1.5 ULN Hold for severe fluid retention

Drug Drug Interactions:Anti fungal azoles may ↑imatenib effect Rifambicin may ↓ imatenib effect Ppi may ↑dermatologic toxic effect of imatenib Digoxin-Tramadol-Codeine their effect may be decreased by imatenib CYP3A4(diltiazem-amlodipine-alprazolamvincristine-nisoldipine) May enhance warfarin effect

KEY COUNSELLINS POINTS

Administrationt

Swallow tabs whole, may be dispersed in water/apple juice, stir until dissolved& use immediately

- **Take with food& large glass of water to↓Gastro intestinal irritation**
- **Pregnancy risk factor:D**
- **May cause sterility in men and menopause in women, discuss with Dr if plan to have children**
- **Avoid grapefruit may ↑imatenib effect**
- **Doses› 400 mg should be administered BID**

Adverse Drug Effects: cardiotoxicity, Fluid retention , myelosuppression, hepato toxicity,photosensitivity.rash, muscle cramps,fever,bleeding, diarrhea,rash

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN

MEDICATION

IMBRUVICA (IBRUTENIB)

DOSE/FDA INDICATION

- Chronic myeloid leukemia,small lymphoblastic lymphoma 420 mg Per oral daily
- Mantle cell lymphoma 560 mg Per oral daily

MONITORING PARAMETERS

Black Box Warning:NONE Base line&Periodically: CBC,Renal&hepatic functions, Uric acid

Drug Drug Interactions: CYP3A4 Substrate

(diltiazem-amlodipine-alprazolam-vincristine-nisoldipine)

KEY COUNSELLINS POINTS

Administrationt

- **Swallow cap whole**
- **Take with or without food with full glass of water**
- **Take missed dose as soon as remembered if on same day**
- **Avoid grape fruits/juice**
- **Pregnancy risk factor:D**

Adverse Drug Effects:

Myelosuppression,edema,dyspnea, Rash,Nause/Vomiting

REFERRENCE:

Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.

NCCN

MEDICATION

INLYTA (AXITINIB)

DOSE/FDA INDICATION

- Advanced renal cell carcinoma 5 mg Per oral BID Doses may be titrated to tolerability& if normotensive up to 10 mg BID if tolerated

MONITORING PARAMETERS

Black Box Warning:NONE Baseline &Periodically:
Liver Functions Tests/billirubin
Thyroid functions,urine analysis,Blood Pressure,heart function
Drug Drug Interactions: CYP3A4 substrate Avoid use with strong CYP3A4 inhibitors if needed ↓dose by 50% then adjust

KEY COUNSELLINS POINTS

Administrationt

Take with or without food with full glass of water

- If missed dose/vomit,an additional dose should not be taken
- Avoid grapefruit/juice
- Encourage BP monitoring at home
- Pregnancy risk factor:D

Adverse Drug Effects:

Hypertensioncrisis,heamorrage,cardiac failure,thromboembolic embolism, dyspnea, Fatigue,Nause/Vomiting

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN

MEDICATION

XELODA (CAPCITABINE)

DOSE/FDA INDICATION

- Metastatic breast cancer, refractory metastatic colon cancer 1250mg/m2 Per oral BID for 2 weeks then one week off

MONITORING PARAMETERS

Black Box Warning: warfarin interaction, frequently monitor INR

Baseline&Periodically:
CBC,Liver Function Tests s,Serum Creat,
INR if concomitant warfarin
Crcl 30-50ml/min↓dose by 25%
for crcl‹30ml/min hold dose
Drug Drug Interactions: Phenytoin,may↑serum phenytoin

KEY COUNSELLINS POINTS

Administrationt

- **Swallow tab whole with water**
- **Taken within 30 min of food with glass of water**
- **Pregnancy risk factor:D**

Adverse Drug Effects:

Myelosuppression,mucsitis,Nause/Vomiting, diarrhea, Hepatotoxicity, yellow eyes or skin,hyperbillirubinaemia Cardiotoxicity,fatigue

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN

MEDICATION

STIVARGA (REGORAFENIB)

DOSE/FDA INDICATION

- Metastatic colorectal cancer after failure of folfox/folfiri,bevacizumab, cetuximab 160 mg Per oral daily on day 1 to day 21 then one week off of 28 days cycle

MONITORING PARAMETERS

Black Box Warning:

Hepatotoxicity Baseline&Periodically: CBC,Liver Functions Tests, Blood Pressure

Drug Drug Interactions: CYP3A4substrate Warfarin may ↑ toxicity of stivarga &bleeding

KEY COUNSELLINS POINTS

Administrationt

- **Swallow tabs whole with water**
- **Take with food**
- **Pregnancy risk factor:D**

Adverse Drug Effects:

Hepatotoxicity,heamorrage,Gastro I ntestinal perforation , Hypertension,mucositis,Nausea/vomiting

REFERRENCE:

Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.

NCCN

MEDICATION

TYKERB (LAPATINIB)

DOSE/FDA INDICATION

- Metastatic HER2+ breast cancer in combination with Xeloda: 1250 mg Per Oral days 1-21
- Metastatic HER2 + breast cancer in combination with Femara: 1500 mg Per Oral daily

MONITORING PARAMETERS

Black Box Warning:Hepatotoxicity Baseline & Periodically: CBC,Liver Functions Tests,ECG,Electrolytes

Drug Drug Interactions: : CYP3A4 substrate Ketoconazole may↑lapatinib plasma conc Carbamazepine may↓lapatinib plasma conc H2 blocker&Proton Pumo Inhibitors, may ↓lapatinib plasma con QT prolongation additive effect with anti arrhythmi

KEY COUNSELLINS POINTS

Administrationt

- **Take on empty stomach 1 hr before or 1 hr after food with full glass of water**
- **Presence of food containing low or high fats alters significantly the bioavailability of lapatinib3-5 folds relative to fasting**
- **Avoid grapefruit/juice may ↑ its plasma level**
- **Pregnancy risk factor:D**

Adverse Drug Effects:

Cardiotoxicity(discontinue if Qt prolongation), Hepatotoxicity (consider dose reduction for moderate enzyme elevation or discontinuation if severe hepatotoxicity develops Pulmonary toxicities(dyspnea-pneumonitis) , Skin rash and pruitis Gastro Intestinal toxicity(diarrhea)

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN

MEDICATION

CASODEX (BICALUTAMIDE)

DOSE/FDA INDICATION

- Metastatic prostate cancer in combination with LHRH agonist

  50 mg Per oral daily

MONITORING PARAMETERS

Black Box Warning:NONE

Baseline& Periodically: Liver Functions Tests(discontinue if ALT›2xUpper Limit Normal or patient develops jaundice

Drug Drug Interactions:

CYP3A4 inhibitors Warfarin: may ↑bleeding Ketoconazole:may ↑plasma conc of bicalutamide Drug disease interaction: Diabetus:loss of glycemic control

Cardiac disease: may cause fluid retention

KEY COUNSELLINS POINTS

Administrationt

May take with or with out food

- **Usually in combination with LHRH agonist**
- **Hazardous agent, use precautions when handling**
- **Contain lactose, use should be carefully considered in pts with galactose intolerence or malabsorbtion**
- **Contra Indication in females**
- **Pregnancy risk factor:X**

Side Effects

Endocrine(gynecomastia,hot flashes,breast tenderness ,Gastro Intestinal toxicity(diarrhea-constipation)

REFERRENCE:

Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.

NCCN

MEDICATION

IBRANCE (PALBOCICLIB)

DOSE/FDA INDICATION

- Advanced or metastatic breast cancer with HR+/HER- post menopausal women for disease progression following endocrine therapy 125 mg Per oral daily for 21 days and one week

MONITORING PARAMETERS

Black Box Warning:NONE

Baseline &Periodically: CBC

Drug Drug Interactions:

CYP3A4 substrate

KEY COUNSELLINS POINTS

Administrationt

Swallow cap whole

- Take with food at same time every day
- Avoid grape fruit/juice
- If missed dose or vomiting occurs do not take replacement dose
- Pregnancy risk factor:D

Advers Drug Effects

Myelosuppression,stomatitis,peripheral neuropathy,alopecia, Nause/Vomiting

REFERRENCE:

Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.

NCCN

MEDICATION

NEXAVAR (SORATINIB)



DOSE/FDA INDICATION

Unresectable hepato cellular carcinoma,Advanced renal cell carcinoma , Differentiated thyroid cancer: 400 mg Per oral BID

MONITORING PARAMETERS

Black Box Warning:NONE
Baseline & Periodically :CBC,Electrolytes,Liver Functions Tests, Blood Pressure,Thyroid function, ECG if at risk for QT prolongation ↓dose if ADE(renal-hepatic dysfunction
Drug Drug Interactions: CYP3A4 substrate,CYP2C9 (doxo rubicin,irinotecan, docetaxel may ↑ their plasma level)
Rifambicin may ↓AUC of sorafenib Paclitaxel&carboplatin may↑sorafenib plasma level May ↑anti coagulant effect of warfarin

KEY COUNSELLINS POINTS

Administrationt

Take on empty stomach 1 hr before or 2 hrs after food

- **Avoid grape fruit/juice**
- **Hazardous agent, use precautions when handling**
- **Pregnancy risk factor:D**
- **Avoid pregnancy while on therapy and for at least 12 weeks after discontinuation of therapy**

Advers Drug Effects

Cardiotoxicity(arrythmia-Hypertension-Myovardial Infarction) Hypophosphatemia-hypocalcemia Myelosuppression,anemia, heomorrage if developed discontue medicine, Pulmonary toxicity

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN

MEDICATION

PURINETHOL (6-MERCAPTO PURINE)



DOSE/FDA INDICATION

- Acute lymphoid leukemia Various regimens exist Typical: 1.5-2.5 mg/kg Per Oral daily

MONITORING PARAMETERS

Black Box Warning:NONE Baseline&Perdiocally:
CBC,Liver Function Tests&billirubin,serum uric acid Use with caution in hepatic impairment,may need dose modification
Crcl‹50 ml/min interval adjustment:every 48 hrs

Drug Drug Interactions:
Allopurinol,Azathioprine: May ↑mercapto purine effect Warfarin: may↓ warfarin effect

KEY COUNSELLINS POINTS

Administrationt

Take on empty stomach

- Adminstration in the evening has demonstrated superior out comes
- Hazardous agent, use precautions when handling
- Do not take with milk or milk based products,there is an enzyme in cow milk can break down mercapto purine
- Pregnancy risk factor: D

Advers Drug Effects

Hepatotoxicity(jaundice&hyperbillirubinemia)occur 1-2 months&can be dose limiting Myelosuppression,skin rashes,stomatitis, photosensitivity

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN

MEDICATION

REVLIMID (LENALIDOMIDE)

DOSE/FDA INDICATION

• Multiple myeloma (with dexamethasone) 25 mg Per oral on day 1-21, then one week off
Myelo displastic syndrome 10 mg per Oral daily

MONITORING PARAMETERS

Black Box Warning: Embryo fetal risk toxicity,thrombo embolism Baseline& Periodically: CBC,Scr,Lver Functions Tests,Thrombosis,

Renal impairment,may need dose modification

Pre existing viral liver diseases or elevated liver enzymes →incraesed risk of hepatic failure,may need dose reduction or interruption

Drug Drug Interactions: Erythrocyte stimulating agent (epoteindarbepotein), estrogen containing agents:↑risk of thrombosis

Digoxin: may ↑digoxin plasma conc

KEY COUNSELLINS POINTS

Administrationt

• Swallow cap whole with water

• Take on empty stomach 1 hr before or 1 hr after food

• Adminstration in the evening has demonstrated superior out comes

• Pregnancy risk factor:X

• Avoid pregnancy while on therapy, use 2 methods of contraceptives,negative pregnancy test must be obtained before initiation of ttt Men should use condom during therapy&at least 4 weeks after discontinuation of therapy

Advers Drug Effects

Thrombo embolism(DVT-PE-MI) Thrombocytopenia-neutropenia Dizziness, tremors Diarrhea,constipation

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN

MEDICATION

JAKAFI (RUXOLITINIB)

DOSE/FDA INDICATION

• High risk myelofibrosis 5-20 mg Per oral BID
Polycythemia vera after hydroxy urea therapy 10 mg Per oral BID dose titrated based on Haemoglobin&Platelets

MONITORING PARAMETERS

BBW:NONE

Base line& Periodically: CBC,Renal,Liver Functions Tests Modify dose for thrombocytopenia,titrate dose based on safety &efficacy Skin lession

Drug Drug Interactions: CYP3A4 substrate Modify dose with CYP3A4 strong inhibitor

KEY COUNSELLINS POINTS

Administrationt

Take with or with out food

• If patient has feeding tube:mix each tab with 40 ml of water,stir for 10 mins (give within 6 hrs of mixing)

• Avoid grape fruit/juice

• When d/c therapy,taper by 5 mg PO BID each week

• Pregnancy risk factor:C

Advers Drug Effects

Myelosuppression,dizziness, headache,weight gain

REFERRENCE:
Package insert of individual medications Drug information hand book24th edition Electronic medical compendium National cancer institute.
NCCN